Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes

The Strength of Synergistic Interaction between Posaconazole and Caspofungin Depends on the Underlying Azole Resistance Mechanism of Aspergillus fumigatus

(2015) Eleftheria Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Analysis of the Aspergillus fumigatus Biofilm Extracellular Matrix by Solid-State Nuclear Magnetic Resonance Spectroscopy

(2015) Courtney Reichhardt et al.   EUKARYOTIC CELL

Aspergillus fumigatus Biofilms: a Comparison of Processing Techniques for Scanning Electron Microscopy of Fungal Mycelium and Extracellular Matrix

(2015) Lydia-Marie Joubert et al.   MICROSCOPY AND MICROANALYSIS

Pharmacokinetics and Safety of Intravitreal Caspofungin

(2014) Ying-Cheng Shen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance

(2014) Cau D. Pham et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cardiac Effects of Echinocandins after Central Venous Administration in Adult Rats

(2014) Christian Koch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance

(2014) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Very-High-Dose Caspofungin Combined with Voriconazole To Treat Central Nervous System Aspergillosis: Substantial Penetration of Caspofungin into Cerebrospinal Fluid

(2014) François Réminiac et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

(2014) N. D. Beyda et al.   CLINICAL INFECTIOUS DISEASES

Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats

(2014) Peipei Sun et al.   MEDICAL MYCOLOGY

Aspergillus Cell Wall and Biofilm

(2014) Anne Beauvais et al.   MYCOPATHOLOGIA

Activities of Systemically Administered Echinocandins againstIn VivoMature Candida albicans Biofilms Developed in a Rat Subcutaneous Model

(2013) Soňa Kucharíková et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis

(2013) Gudrun Würthwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Species-Specific and Drug-Specific Differences in Susceptibility of Candida Biofilms to Echinocandins: Characterization of Less Common Bloodstream Isolates

(2013) Maria Simitsopoulou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Anidulafungin versus Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible Candida parapsilosis Isolates with Different Degrees of Caspofungin Susceptibility

(2013) Dimitra Dimopoulou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths

(2013) Ronald G. Hall et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Amphotericin B- and Voriconazole-Echinocandin Combinations against Aspergillus spp.: Effect of Serum on Inhibitory and Fungicidal Interactions

(2013) Antigoni Elefanti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroStudy of Sequential Fluconazole and Caspofungin Treatment against Candida albicans Biofilms

(2013) Semanti Sarkar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Caspofungin in Critically Ill Patients on Continuous Renal Replacement Therapy

(2013) Stefan Weiler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Paradoxical Growth of Candida albicans in the Presence of Caspofungin Is Associated with Multiple Cell Wall Rearrangements and Decreased Virulence

(2013) Cristina Rueda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reflections on the Approach to Treatment of a Mycologic Disaster

(2013) David A. Stevens   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A severe case of haemodynamic instability during anidulafungin administration

(2013) M. Fink et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Cardiac effects of echinocandin preparations - three case reports

(2013) C. Lichtenstern et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review

(2013) Tark Kim et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics of Caspofungin in Two Patients with Burn Injuries

(2012) V. Jullien et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination viaIn VivoPharmacodynamic Evaluation against Candida glabrata with and withoutfksMutations

(2012) Alexander Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Experimental Central Nervous System Aspergillosis Therapy: Efficacy, Drug Levels and Localization, Immunohistopathology, and Toxicity

(2012) Karl V. Clemons et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin

(2012) Louise A. Walker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

(2012) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

(2012) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

(2012) W.W. Hope et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Nonsteroidal Antiinflammatory Drug Diclofenac Potentiates the In Vivo Activity of Caspofungin Against Candida albicans Biofilms

(2012) Anna Bink et al.   JOURNAL OF INFECTIOUS DISEASES

Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A

(2012) Ravikumar B Shinde et al.   Annals of Clinical Microbiology and Antimicrobials

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Caspofungin and Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2011) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum

(2011) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

(2011) O. A. Cornely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activities of Anidulafungin and Other Antifungal Agents against Biofilms Formed by Clinical Isolates of Different Candida and Aspergillus Species

(2011) Barbara Fiori et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin ResistanceIn Vivo

(2011) Keunsook K. Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

(2011) Alison G. Freifeld et al.   CLINICAL INFECTIOUS DISEASES

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report

(2011) Angela L. Ngai et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales

(2011) Roxana G. Vitale et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin

(2011) S. Kucharikova et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Transcriptional Regulation of Chitin Synthases by Calcineurin Controls Paradoxical Growth of Aspergillus fumigatus in Response to Caspofungin

(2010) J. R. Fortwendel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four DifferentCandidaSpecies

(2010) Fernando C. Bizerra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential Aspergillus lentulus Echinocandin Susceptibilities Are Fksp Independent

(2010) J. F. Staab et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection

(2010) J. L. Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study

(2010) R Herbrecht et al.   BONE MARROW TRANSPLANTATION

Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants

(2010) Elizabeth M. Migoya et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia

(2010) Johan A. Maertens et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of the In Vitro Kinetic Activity of Caspofungin against Candida glabrata

(2009) V. Nagappan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Anidulafungin Is Fungicidal and Exerts a Variety of Postantifungal Effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates

(2009) K. T. Nguyen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vivobiofilm composition ofAspergillus fumigatus

(2009) Céline Loussert et al.   CELLULAR MICROBIOLOGY

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

(2009) Robert F. Betts et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia

(2009) M. Lafaurie et al.   CLINICAL MICROBIOLOGY AND INFECTION

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

(2009) C. Viscoli et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS

(2009) Theoklis Zaoutis et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients

(2009) T. E. Zaoutis et al.   PEDIATRICS

Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers

(2008) M. Neely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans

(2008) N. Venisse et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

(2008) J. D. Cleary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age

(2008) X. Saez-Llorens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus: the Challenge of Azoles versus Echinocandins

(2008) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans

(2008) N. P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection

(2008) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aspergillus fumigatus Forms Biofilms with Reduced Antifungal Drug Susceptibility on Bronchial Epithelial Cells

(2008) M. J. Seidler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis

(2008) Yasmine Nivoix et al.   CLINICAL INFECTIOUS DISEASES

Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral Mucormycosis

(2008) Caitlin Reed et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis

(2008) E.C. van Asbeck et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis

(2008) R. E. Lewis et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms

(2008) E. Mowat et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

A Possible Mechanism for Synergy between Antifungal Therapy and Immune Defenses

(2008) David A. Stevens   JOURNAL OF INFECTIOUS DISEASES

Caspofungin Modulates Inflammatory Responses toAspergillus fumigatusthrough Stage‐Specific Effects on Fungal β‐Glucan Exposure

(2008) T. M. Hohl et al.   JOURNAL OF INFECTIOUS DISEASES

Caspofungin‐Mediated β‐Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity againstAspergillusand Non‐AspergillusHyphae

(2008) Gregory A. Lamaris et al.   JOURNAL OF INFECTIOUS DISEASES